Related references
Note: Only part of the references are listed.Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis
Motoyasu Kojima et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review
Xiaodan Lv et al.
ENDOCRINOLOGY DIABETES & METABOLISM (2020)
Peroxisome-derived lipids regulate adipose thermogenesis by mediating cold-induced mitochondrial fission
Hongsuk Park et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Liraglutide Decreases Hepatic Inflammation and Injury in Advanced Lean Non-Alcoholic Steatohepatitis
David H. Ipsen et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2018)
Dysregulation of the NUDT7-PGAM1 axis is responsible for chondrocyte death during osteoarthritis pathogenesis
Jinsoo Song et al.
NATURE COMMUNICATIONS (2018)
Peroxisomal β-oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease
Maria E. Moreno-Fernandez et al.
JCI INSIGHT (2018)
Hepatocyte-specific, PPARγ-regulated mechanisms to promote steatosis in adult mice
Abigail Wolf Greenstein et al.
JOURNAL OF ENDOCRINOLOGY (2017)
PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD
Barbara Gross et al.
NATURE REVIEWS ENDOCRINOLOGY (2017)
Hepatic lipid metabolism and non-alcoholic fatty liver disease in aging
Zhenwei Gong et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2017)
SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology
Hitoshi Shimano et al.
NATURE REVIEWS ENDOCRINOLOGY (2017)
Non-alcoholic fatty liver disease: An expanded review
Mark Benedict et al.
WORLD JOURNAL OF HEPATOLOGY (2017)
Dual Outcomes of Rosiglitazone Treatment on Fatty Liver
Mingming Gao et al.
AAPS JOURNAL (2016)
Nuclear receptors and nonalcoholic fatty liver diseases
Matthew C. Cave et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2016)
No peroxisome is an island - Peroxisome contact sites
Nadav Shai et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2016)
Antiobesity efficacy of GLP-1 receptor agonist liraglutide is associated with peripheral tissue-specific modulation of lipid metabolic regulators
Juan Decara et al.
BIOFACTORS (2016)
Peroxisome-mitochondria interplay and disease
Michael Schrader et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2015)
Recent insights into the biological functions of liver fatty acid binding protein 1
GuQi Wang et al.
JOURNAL OF LIPID RESEARCH (2015)
The glucagon-like peptide 1 receptor agonist enhances intrinsic peroxisome proliferator-activated receptor γ activity in endothelial cells
Hirohisa Onuma et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
Understanding the relationship between DNA methylation and histone lysine methylation
Nathan R. Rose et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2014)
Peroxisomes: A Nexus for Lipid Metabolism and Cellular Signaling
Irfan J. Lodhi et al.
CELL METABOLISM (2014)
The MLL3/MLL4 Branches of the COMPASS Family Function as Major Histone H3K4 Monomethylases at Enhancers
Deqing Hu et al.
MOLECULAR AND CELLULAR BIOLOGY (2013)
Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis
Seung-Hoi Koo
CLINICAL AND MOLECULAR HEPATOLOGY (2013)
Roles of PPARs in NAFLD: Potential therapeutic targets
Anne Tailleux et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2012)
The Inflammatory Response in Acyl-CoA Oxidase 1 Deficiency (Pseudoneonatal Adrenoleukodystrophy)
H. I. El Hajj et al.
ENDOCRINOLOGY (2012)
Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis
Anabela P. Rolo et al.
FREE RADICAL BIOLOGY AND MEDICINE (2012)
PPARs at the crossroads of lipid signaling and inflammation
Walter Wahli et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2012)
GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
Jinmi Lee et al.
DIABETES & METABOLISM JOURNAL (2012)
Role for PPARγ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts
Eva Moran-Salvador et al.
FASEB JOURNAL (2011)
Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced bya high-fat diet in nonalcoholic steatohepatitis
Gianluca Svegliati-Baroni et al.
LIVER INTERNATIONAL (2011)
Genetic control of de novo lipogenesis: role in diet-induced obesity
Maggie S. Strable et al.
CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY (2010)
Obesity and Nonalcoholic Fatty Liver Disease: Biochemical, Metabolic, and Clinical Implications
Elisa Fabbrini et al.
HEPATOLOGY (2010)
Hepatic Lipotoxicity and the Pathogenesis of Nonalcoholic Steatohepatitis: the Central Role of Nontriglyceride Fatty Acid Metabolites
Brent A. Neuschwander-Tetri
HEPATOLOGY (2010)
Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)
Giovanni Musso et al.
PROGRESS IN LIPID RESEARCH (2009)
Non-alcoholic fatty liver disease and the metabolic syndrome: An update
R. Scott Rector et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects
Jukka Westerbacka et al.
DIABETES (2007)
Caveolin-1 is essential for liver regeneration
Manuel A. Fernandez et al.
SCIENCE (2006)
Targeted deletion of FATP5 reveals multiple functions in liver metabolism: Alterations in hepatic lipid Homeostasis
H Doege et al.
GASTROENTEROLOGY (2006)
Nonalcoholic fatty liver disease: From steatosis to cirrhosis
GC Farrell et al.
HEPATOLOGY (2006)
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
DE Kleiner et al.
HEPATOLOGY (2005)
Liver peroxisome proliferator-activated receptor γ contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass
O Gavrilova et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes
K Matsusue et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones
L Chao et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Share Paper
